We came across a bullish thesis on GRAIL, Inc. on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.’s share was trading at $32.42 as of September 3rd.
Photo by National Cancer Institute on Unsplash
GRAIL (NASDAQ: GRAL) represents a compelling risk-reward opportunity in early cancer detection through its Galleri blood test, the first commercially viable multi-cancer early detection (MCED) platform. The company, spun out of...
